These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 2191821)

  • 1. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).
    Ponto LL; Schoenwald RD
    Clin Pharmacokinet; 1990 Jun; 18(6):460-71. PubMed ID: 2191821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).
    Ponto LL; Schoenwald RD
    Clin Pharmacokinet; 1990 May; 18(5):381-408. PubMed ID: 2185908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative study of pharmacokinetics and effects on urinary secretion of electrolytes of furosemide and furosemide-amiloride in healthy subjects].
    Kantelip JP; Aiache JM; Beyssac E; Abella ML
    Therapie; 1991; 46(6):475-9. PubMed ID: 1819153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.
    Klausner EA; Lavy E; Stepensky D; Cserepes E; Barta M; Friedman M; Hoffman A
    J Clin Pharmacol; 2003 Jul; 43(7):711-20. PubMed ID: 12856384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The pharmacodynamic and pharmacokinetic characteristics of furosemide and furesis].
    Noskov VB; Goncharov IB; Kovachevich IV; Kodratenko SN; Starodubtsev AK; Sokolova EV
    Eksp Klin Farmakol; 1999; 62(3):32-6. PubMed ID: 10439945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of Urinary Output Response to IV Furosemide in Acute Kidney Injury: A Pharmacokinetic/Pharmacodynamic Study.
    Silbert BI; Ho KM; Lipman J; Roberts JA; Corcoran TB; Morgan DJ; Pavey W; Mas E; Barden AE; Mori TA
    Crit Care Med; 2016 Oct; 44(10):e923-9. PubMed ID: 27183025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.
    Hammarlund-Udenaes M; Benet LZ
    J Pharmacokinet Biopharm; 1989 Feb; 17(1):1-46. PubMed ID: 2654356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
    Lesne M
    Arzneimittelforschung; 1988 Jan; 38(1A):160-3. PubMed ID: 3370062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide.
    Vree TB; van den Biggelaar-Martea M; Verwey-van Wissen CP
    Br J Clin Pharmacol; 1995 Jun; 39(6):692-5. PubMed ID: 7654491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The pharmacodynamics and pharmacokinetics of furosemide during ordinary life activities and during head-down tilt hypokinesia in a healthy subject].
    Noskov VB; Goncharov IV; Kovachevich IV; Repenkova LG; Kodratenko SN; Starodubtsev AK
    Eksp Klin Farmakol; 1998; 61(4):29-33. PubMed ID: 9783105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of loop diuretics.
    Brater DC
    Drugs; 1991; 41 Suppl 3():14-22. PubMed ID: 1712712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics and pharmacodynamics of furosemide in liver cirrhosis].
    Tesar V; Kotal P; Petrtýl J; Bukovská J; Kozáková M; Brodanová M; Horký K; Kordac V
    Cas Lek Cesk; 1990 May; 129(21):657-64. PubMed ID: 2369756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations on pharmacodynamics and pharmacokinetics: can everything be explained by the extent of drug binding to its receptor?
    Castañeda-Hernández G; Granados-Soto V
    Can J Physiol Pharmacol; 2000 Mar; 78(3):199-207. PubMed ID: 10721811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of intravenous frusemide bolus in critically ill patients.
    Huang A; Luethi N; Mårtensson J; Bellomo R; Cioccari L
    Crit Care Resusc; 2017 Jun; 19(2):142-149. PubMed ID: 28651510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Localization of the action of furosemide and triamterene in the nephron by means of correlating their pharmacokinetics and pharmacodynamics].
    Lebedev AA; Munina II
    Farmakol Toksikol; 1989; 52(1):44-7. PubMed ID: 2707420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with high doses of loop diuretics in chronic renal failure.
    Ritz E; Fliser D; Nowicki M; Stein G
    Nephrol Dial Transplant; 1994; 9 Suppl 3():40-3. PubMed ID: 8072724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficiency concept in pharmacodynamics.
    Alván G; Paintaud G; Wakelkamp M
    Clin Pharmacokinet; 1999 May; 36(5):375-89. PubMed ID: 10384860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
    Shoaf SE; Bramer SL; Bricmont P; Zimmer CA
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):213-22. PubMed ID: 17703139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
    Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics and pharmacokinetics of furosemide-retard and furosemide-retard/triamterene.
    Heimsoth V; Loew D; Schuster O
    Eur J Drug Metab Pharmacokinet; 1988; 13(3):161-4. PubMed ID: 3240762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.